Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Research by Draper and Pfizer Demonstrates Colon-on-Chip Tissue Models


News provided by

Draper

Oct 02, 2023, 11:00 ET

Share this article

Share toX

Share this article

Share toX

Researchers from Draper and Pfizer tested human colon tissue models using Draper’s PREDICT96, one of the first platforms to assess permeability across multiple donors and IBD dose treatments. Draper
Researchers from Draper and Pfizer tested human colon tissue models using Draper’s PREDICT96, one of the first platforms to assess permeability across multiple donors and IBD dose treatments. Draper

Treatments that target inflammation directly don't always work for some people with inflammatory bowel disease. However, new drug discovery approaches that focus on the health of the intestinal lining hold promise for improving treatment regimes.

CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire-PRWeb/ -- Science is stalled in its efforts to develop more effective treatments for inflammatory bowel disease (IBD), in part because most treatments focus on reducing inflammation but ignore the importance of repairing the bowel's epithelial barrier. Now, new research suggests that science might want to pursue a mix of both strategies in addressing IBD—restore the intestinal barrier to a healthy state and reduce inflammation. Patients could see improved outcomes and reach higher treatment response rates.

IBD, which includes both ulcerative colitis and Crohn's disease, is increasing around the world, with an incidence rate of 4.9M cases worldwide. Contributing causes include genetic predisposition, environmental toxicity and an imbalance in a person's microbiome. Common symptoms include diarrhea, rectal bleeding, anemia, abdominal pain and malnutrition.

"A potential reason that current treatments have significant non-response or loss-of-response could be their focus on suppressing inflammatory response but failure to heal the epithelial barrier," researchers at Draper and Pfizer said in a new paper in the journal Nature Scientific Reports.

Post this

In IBD drug discovery, most treatment strategies target immune cells and inflammation of the bowel. However, another key element is frequently overlooked: the epithelial barrier that lines the intestinal tract, which provides protection from the intestine contents. When the barrier breaks down, through irritation from intestine contents or from a disease condition, the immune system is activated. The result is a continuous recurrence of inflammation. "We call it a positive feedback loop," says Elizabeth Wiellette, Ph.D., of Draper. "Even as inflammation is suppressed, the cycle can re-initiate if the epithelial barrier remains damaged, leading to sub-effective treatments."

Wiellette is a biologist and co-author of a paper published in the prestigious journal [Nature Scientific Reports. A research team from Draper and Pfizer experimented using human organ tissues-on-a-chip. The team seeded, grew and tested human colon epithelial tissue models in Draper's PREDICT96 high-throughput microfluidic testing platform.

Among the findings, Wiellette and her colleagues demonstrated that Draper's microfluidic device can be used to reconstruct human colon epithelial physiology and function at the cellular and tissue level and quantify dynamic drug-interaction with bowel tissue in real time. The platform showed it has the potential to screen new drugs for therapeutic effect without the need for animal models, elucidate the mechanism of action on barrier cells and be scaled to provide pre-clinical studies with ample statistical power.

The PREDICT96 colon model combines primary human colon cells and a high-throughput framework with integrated pumping and trans-epithelial electrical resistance (TEER) measurements that make it one of the first systems to efficiently and sensitively assess permeability across multiple donors and many dose treatments. Researchers studied physiologically relevant human intestinal biology in a modality that can support the bandwidth required for applications such as therapeutic and small molecule screening.

"A potential reason that current treatments have significant non-response or loss-of-response could be their focus on suppressing inflammatory response but failure to heal the epithelial barrier," the authors said. Treatments that target inflammation directly but fail to heal the intestinal barrier may fail to thoroughly suppress the disease state, they said.

Unlike most microfluidic testing platforms that have fewer than a dozen replicates, Draper's platform can hold 96 individual organ tissue models in one microfluidic culture plate. A key feature is a culture plate lid that provides integrated pumping and sensing, including 192 individual and actively-controlled micropumps and 384 individually addressable electrodes configured to make electrical measurements within each of the 96 tissue models.

In the paper, the authors point out that competing intestine-on-chip platforms are highly specialized and typically support only single or small replicate numbers, rendering them less useful for studies that benefit from high throughput capacity, such as drug discovery.

The paper was co-written by Elizabeth Marr, Thomas Mulhern, Michaela Welch, Philip Keegan, Hesham Azizgolshani, Joseph Charest and Timothy Petrie of Draper; and Marion Kasaian, Celia Caballero Franco and Bryce Johnson of Pfizer.

Draper has modeled intestine, liver, kidney, lung and other organs and has partnered with a pharmaceutical company and consumer products company to manufacture configurations of its PREDICT-96 human organ system. Draper also has collaborated with a university to link organ chips together to predict the effects of potentially toxic chemicals and drugs on the human reproductive system.

Visit Draper at https://www.draper.com/

Media Contact

Dan Dent, Draper, 6172582462, [email protected], https://www.draper.com/ 

SOURCE Draper

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.